UroToday - The Global Online Community of Urologists
Reno, Nevada (UroToday.com) -- Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for …
UroToday - The Global Online Community of Urologists
While the data are still maturing, median time to PSA progression is currently at 16.6 months. Read More. UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
ASCO GU 2022: PROpel: Phase III Trial of Olaparib and ... - UroToday
(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castration-resistant …
ASCO GU 2023 - UroToday
ASCO GU 2023: Identifying Prostate Cancer Patient Subgroups Based on Their Preferences for Key Attributes of Androgen Deprivation Therapies. ASCO GU 2023: Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer. ASCO GU 2023: Radium-223 for mCRPC, a Real-World Experience Study from 7 Galician Medical Centers.
Bladder Cancer Advances in 2020 and 2021 - UroToday
2021年2月3日 · In May 2020, at the virtual ASCO meeting, investigators updated the study results covering a median follow-up time of 28.4 months. 13 The overall rate of complete response (CR) was 41%, with a median duration of response of 16.2 months; in the overall efficacy analysis, 19% of patients who received pembrolizumab had a CR that exceeded 12 months.
ASCO GU 2024 - UroToday
ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15) ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS ...
ASCO 2021 - UroToday
ASCO 2021: Safety and Efficacy of AMG 160, a Half-Life Extended BiTE Immune Therapy Targeting PSMA, and Other Therapies for Metastatic Castration-Resistant Prostate Cancer. ASCO 2021: Complementary Detection of Genomic Alterations in Metastatic Castration Resistant Prostate Cancer From CheckMate 9KD Through Analyses of Tumor Tissue and Plasma DNA.
Prostate Cancer - UroToday
September 25, 2024. Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. September 25, 2024. Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.
PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or
In an oral presentation in the New Trials Update session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Karim Fizazi presented a discussion of the results of PROfound Study, Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound), examining the role of olaparib among ...
Conference Highlights - UroToday
2024 American Urological Association (AUA) 2024 Southeastern Section of the AUA. 2024 AUA Annual Urology Advocacy Summit. 2023 Annual Meeting. 2023 Southeastern Section. ANZUP Mini Annual Scientific Meeting (ASM) 2021 Annual Meeting. Bladder Cancer Advocacy Network (BCAN) BCANTT 2024.